---
title: Highly sensitive therapeutic drug monitoring of infliximab in serum by targeted
  mass spectrometry in comparison to ELISA data
date: '2024-02-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38424496/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240301170524&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In this study, a semi-automated workflow was employed and
  tested with 8 patients and corresponding replicates (n = 3-4). We demonstrated the
  robust implementation of calibration curves for the absolute quantification of infliximab
  in patient samples, with coefficients of variation ranging from 0.5 to 9%. Taken
  together, we have developed a platform enabling the rapid (2 days of sample preparation
  and 30 min of measurement time per sample) and robust quantification of ...'
disable_comments: true
---
CONCLUSIONS: In this study, a semi-automated workflow was employed and tested with 8 patients and corresponding replicates (n = 3-4). We demonstrated the robust implementation of calibration curves for the absolute quantification of infliximab in patient samples, with coefficients of variation ranging from 0.5 to 9%. Taken together, we have developed a platform enabling the rapid (2 days of sample preparation and 30 min of measurement time per sample) and robust quantification of ...